References
- Schmitz N, Dreger P, Glass B, et al. Allogeneic transplantation in lymphoma: current status. Haematologica 2007; 92: 1533–1548
- Laport G G. Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review. Leuk Lymphoma 2008; 49: 1854–1859
- Steingass S K. Hematopoietic cell transplantation in non-Hodgkin's lymphoma. Semin Oncol Nurs 2006; 22: 107–116
- Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Socie'te’ Française de Greffe de Moe¨lle Osseuse-The'rapie Cellulaire. J Clin Oncol 2008; 26: 2512–2518
- Mcfarland W, Granville N B, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 1959; 14: 503–521
- Kessinger A, Armitage J O, Smith D M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260–1265
- Niitsu N, Okamoto M, Nakamine H, et al. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 2008; 26: 152–158
- Nachbaur D, Oberariquner W, Fritsch E, et al. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Eur J Haematol 2002; 66: 43–49
- Rodríguez J, Conde E, Gutiérrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78: 290–296
- Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110: 1278–1282
- Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant 2003; 32: 57–63
- Verdonck L F, Dekker A W, Lokhorst H M, et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205
- Song K W, Ba rnett M J, Gascoyne R D, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 2007; 18: 535–540
- Guinan E C, Boussiotis V A, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704–1714
- Goldman F D, Rumelhart S L, DeAlacron P, et al. Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant 2000; 25: 943–948
- Ji S Q, Chen H R, Yan H M, et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005; 36: 349–354
- Ji S Q, Chen H R, Wang H X, et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861–866
- Wang H X, Yan H M, Duan L N, et al. Haploidentical hematopoietic stem cell transplantation in children hematologic malignancies with G-CSF mobilized marrow grafts without T cell depletion: a single center report of 45 cases. Pediatr Hematol Oncol 2009; 26: 119–128
- Lu D P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073
- Chen X H, Zhang C, Zhang X, et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 266–273
- Harris N L, Jaffe E S, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Chen A I, McMillan A, Negrin R S, et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008; 14: 741–747
- Soussain C, Souleau B, Gabarre J, et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999; 33: 543–550
- Hosing C, Saliba R M, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 737–744
- Miglino M, Santini G, Grasso R, et al. Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation. Haematologica 2001; 86: 706–714
- Jacquy C, Lambert F, Soree A, et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging. Bone Marrow Transplant 1999; 23: 681–686
- Hari P, Carreras J, Zhang M J, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245
- Isola L M, Scigliano E, Skerrett D, et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997; 20: 1033–1037
- Ji S, Chen H, Wang H, et al. low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells. Chin Med J 2001; 114: 191–195
- Serody J S, Sparks S D, Lin Y, et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434–440
- Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF) primed allogeneic bone marrow: significantly less graft-vs-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186–3191
- LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009; 87: 966–974
- Feng X, Kajigaya S, Solomou E E, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008; 111: 3675–3683
- Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387–1394
- Zhang L, Arrington S, Keung Y K. Guillain-Barre’ syndrome after transplantation. Leuk Lymphoma 2008; 49: 291–297
- Ooi J, Takahashi S, Tajika K, et al. Immune-mediated optic neuritis after unrelated allogeneic bone marrow transplantation. Blood 1998; 91: 2619–2620